

Nickolas Papadopoulos, Ph.D.

Dr. Nickolas Papadopoulos is internationally known as a co-discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC), one of the most common hereditary forms of cancer, earlier in his career. He is known for the development of diagnostic tests and he is considered an expert in cancer genetics and diagnostics. He was part of the interdisciplinary team that was first to sequence all of the protein coding genes, determine genetic alterations and construct expression profiles of four common tumor types. Later he was involved in the identification of genetic alterations that drive tumorigenesis in multiple tumor types. Noteworthy discoveries he has made include the identification of novel mutations in chromatin remodeling genes in ovarian clear cell carcinomas and pancreatic neuroendocrine tumors. Currently, he is focused on translating the genetic information derived from cancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer. He is a co-developer of sensitive methods for the detection of tumor DNA in liquid biopsy. Recently, he developed CancerSEEK, a blood test for the early detection of multiple cancers. He is also the co-founder of two companies that develop diagnostics for cancer.

Current Appointment

2012 – present Professor of Oncology and Pathology
Director of Translational Genetics, Ludwig Center at Johns Hopkins
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore,
Maryland

Education and Training

1980 – 1985 Bachelor of Science, B.S., in Biology, Aristotelion University of Thessaloniki,
Thessaloniki, Greece
1986 – 1988 Masters in Science, M.S., in Biology, University of Houston – University Park, Houston,
TX
1988 – 1992 Doctor of Philosophy, Ph.D., in Biomedical Sciences, University of Texas Health Science
Center at Houston, Houston, TX
1992 – 1993 Fogerty Fellowship, National Institutes on Aging, Gerontology Research Center, NIH,
Baltimore
1993 – 1996 Postdoctoral Fellowship in Oncology, Johns Hopkins University School of Medicine

Professional Experience

Academia

1983 – 1985 Undergraduate Research, Department of Genetics, Aristotelion University of
Thessaloniki, Thessaloniki, Greece
1986 – 1988 Graduate Research, Department of Biology, University of Houston – University, Houston,
TX
1988 – 1992 Graduate Research, Departments of Pharmacology and Regulatory Biology, University of
Texas Health Science Center at Houston, Houston, TX
1992 – 1993 Fogerty Fellowship, National Institutes on Aging, Gerontology Research Center, NIH,
Baltimore
1993 – 1996 Postdoctoral Fellowship, Johns Hopkins Oncology Center
1996 – 1997 Research Associate, Johns Hopkins Oncology Center
1997 – 2000 Assistant Professor of Pathology, Columbia University, Presbyterian Hospital, New York,
NY
1999 – 2000 Assistant Professor, Institute for Cancer Genetics, Columbia University, New York, NY
2000 – 2006 Adjunct Assistant Professor, Institute for Cancer Genetics, Columbia University, New
York, NY
2005 – 2006 Visiting Associate Professor, Johns Hopkins Oncology Center, Baltimore, MD
2006 – 2012 Associate Professor of Oncology, Johns Hopkins School of Medicine

- 2006 – Director, Translational Genetics, Ludwig Center for Cancer Genetics and Therapeutics
Johns Hopkins Sidney Kimmel Cancer Center
2012 – Professor of Oncology, Johns Hopkins School of Medicine

Industry

- 2000 – 2004 Chief Scientific Officer, GMP Genetics, Inc., Waltham, MA
2002 – 2004 Vice President, GMP Genetics, Inc., Waltham, MA
2004 – 2005 Consultant, GMP Genetics, Waltham, MA
2004 – 2005 Consultant, Helicos Biosciences, Inc., Cambridge, MA
2006 - 2007 Consultant, Exact Sciences, Inc.
2007 - 2008 Consultant, Gerson Lehrman Group Councils
2014 – 2017 Consultant, Sysmex-Inostics
2014 – 2019 President, PapGene Inc
2019 – 2020 Board of Directors for Thrive Inc

Co-Founder

- 2009 **Inostics** : A company based on plasma diagnostics. Acquired by Sysmex.
2010 **PGDx Inc**: A company that provides advanced cancer genome analyses.
2014 **PapGene Inc**: A company focused on bringing molecular cytology to the clinic.
2019 **Thrive**. A company developing non-invasive tests for the detection of cancer
2021 **ManaTBio**. A company developing immunotherapies

Bibliography

[My Bibliography - NCBI \(nih.gov\)](#)